Home / Stocks / Iol Chem And Pharma Ltd
IOLCP

Iol Chem And Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹191.78

Change

+2.04 (1.08%)

Open

₹189.74

Prev. Close

₹189.74

Day High

₹194.2

Day Low

₹186.05

Volume Analysis

Traded

1,388,012

Delivered

401,195

Delivery %

28.9%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (1)

  • •Low return on equity (8.41%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹203.46 ₹198.83 ₹195.31 ₹190.68 ₹187.16 ₹182.53 ₹179.01
Fibonacci ₹198.83 ₹195.72 ₹193.79 ₹190.68 ₹187.57 ₹185.64 ₹182.53
Camarilla ₹194.02 ₹193.27 ₹192.53 ₹190.68 ₹191.03 ₹190.29 ₹189.54

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+133.37%

1 Week

-6.49%

1 Month

+10.07%

3 Months

+13.13%

6 Months

+61.53%

1 Year

+109.32%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹149.54

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.52%

Net margin 7.38% × asset turnover 1.22x × equity multiplier 1.28x

Company Overview

Sector

Healthcare

Market Cap

₹5,587 Cr

P/E (TTM)

26.4

ROE

8.41%

Book Value

₹65.6

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Iol Chem And Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Growth (6/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.41%). FII holding has been rising.

TopFund Score — Fundamentals Quality

59/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

6

Valuation

54

Cash Flow

44

Corporate Governance

100

Momentum

79

Institutional Ownership

46

Business Quality

53

Risk & Volatility

67

Liquidity

59

From Screener.in

  • +Company is expected to give good quarter
  • +Company has been maintaining a healthy dividend payout of 22.1%
  • −Stock is trading at 2.91 times its book value
  • −Company has a low return on equity of 7.72% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Company clarified no undisclosed event behind recent trading volume increase.

Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume.

Transcript of Earning Call on the Q2 & H1 FY27 Financial Results

Audio recording released for Q2 and H1 FY27 earnings call held on 2 November 2026.

Investor Presentation- Q2 & H1 FY27

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 545 520 504 502 526 523 528 552 568 580 619 756 795
Expenses + 481 476 454 451 484 476 465 490 510 523 527 653 686
Operating Profit 64 44 50 51 42 47 63 62 57 57 92 103 109
OPM % 12.0% 9.0% 10.0% 10.0% 8.0% 9.0% 12.0% 11.0% 10.0% 10.0% 15.0% 14.0% 14.0%
Other Income + 7 8 8 7 6 4 5 7 7 -6 2 8 6
Interest 4 4 3 2 4 4 4 4 3 4 3 4 5
Depreciation 16 16 16 17 18 19 19 20 20 20 20 21 22
Profit before tax 51 32 37 40 26 28 45 46 40 28 71 87 87
Tax % 26.0% 28.0% 26.0% 24.0% 26.0% 26.0% 30.0% 25.0% 26.0% 25.0% 25.0% 26.0% 25.0%
Net Profit + 38 23 28 30 19 21 31 34 30 21 53 64 65
EPS in Rs 1 1 1 1 1 1 1 1 1 1 2 2 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 1 -1 -14 -11 -4 1 5 10 8 11 17 37 40

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 385 580 711 983 1,685 1,894 1,967 2,184 2,217 2,133 2,079 2,319 2,751
Expenses + 373 529 608 863 1,276 1,321 1,375 1,925 1,991 1,902 1,877 2,049 2,388
Operating Profit 11 51 102 120 410 574 592 259 226 231 202 270 363
OPM % 2.9% 9.0% 14.0% 12.0% 24.0% 30.0% 30.0% 12.0% 10.0% 11.0% 10.0% 12.0% 13.0%
Other Income + 1 1 1 6 10 16 24 17 25 30 22 9 10
Interest 59 61 68 64 51 21 6 8 16 16 15 15 16
Depreciation 29 30 30 30 32 36 39 43 46 63 72 80 84
Profit before tax -75 -39 6 31 336 533 571 225 189 182 138 184 272
Tax % -12.0% 4.0% 21.0% 12.0% 30.0% 32.0% 22.0% 25.0% 26.0% 26.0% 27.0% 25.0% —
Net Profit + -67 -40 5 28 237 361 445 168 139 134 101 138 203
EPS in Rs -3 -1 0 1 8 13 15 6 5 5 3 5 7
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 5.0% 8.0% 14.0% 17.0% 22.0% 23.0% 21.0% —
Sales growth -32 51 22 38 71 12 4 — 2 -4 -3 12 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 160 129 132 160 417 757 1,202 1,334 1,449 1,553 1,629 1,740 1,867
Borrowings + 400 453 447 422 284 59 3 44 80 33 117 135 201
Other Liabilities + 94 135 182 214 184 297 347 526 435 600 577 653 704
Total Liabilities 702 772 817 852 942 1,170 1,610 1,962 2,022 2,244 2,382 2,587 2,831
Fixed Assets + 403 400 374 406 412 469 512 561 752 933 1,171 1,182 1,191
CWIP 4 4 21 7 27 19 48 105 90 101 22 96 189
Investments 0 0 0 0 0 0 1 2 20 20 21 21 21
Other Assets + 295 369 422 439 503 682 1,048 1,294 1,161 1,190 1,169 1,289 1,429
Total Assets 702 772 817 852 942 1,170 1,610 1,962 2,022 2,244 2,382 2,587 2,831
Equity Capital 48 56 56 56 57 57 59 59 59 59 59 59 59

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -47 18 83 120 273 471 380 93 122 290 179 214
Cash from Investing Activity + -5 -27 -23 -50 -63 -184 -317 -121 -120 -191 -154 -198
Cash from Financing Activity + 50 9 -60 -70 -197 -272 -58 -2 -4 -92 46 -29
Net Cash Flow -2 0 1 -1 13 15 4 -29 -2 6 70 -13
Free Cash Flow -53 -9 61 71 213 391 272 -58 -87 17 -34 43
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -413 34 82 105 83 102 88 60 75 144 97 93

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 48.19% → 62.28%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 49.27% 50.11% 50.34% 50.11% 45.81% 45.84% 44.76% 45.1% 45.26% 40.78% 32.41% 30.16%
Promoters 48.19% 48.19% 48.19% 48.19% 52.62% 52.62% 52.62% 52.62% 52.62% 57.48% 62.28% 62.28%
FII 2.18% 1.4% 1.39% 1.63% 1.49% 1.47% 2.59% 2.25% 2.08% 1.72% 4.87% 7.26%
DII 0.36% 0.29% 0.09% 0.07% 0.08% 0.07% 0.02% 0.05% 0.03% 0.02% 0.43% 0.3%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Iol Chem And Pharma Ltd (this stock) 5,587 26.4 2.91 8.41%
Sahajanand Medical Tech L 5,427 75.6 — 10.4%
Artemis Med Service Ltd 5,415 46.2 5.47 12.0%
Senores Pharmaceuticals L 5,409 40.5 5.39 13.4%
Orchid Pharma Limited 5,296 293.0 2.95 1.49%
Innova Captab Limited 5,938 35.6 5.09 13.7%
Morepen Lab. Ltd 5,061 26.8 3.67 5.33%

Which Mutual Funds Hold Iol Chem And Pharma Ltd?

Frequently Asked Questions about Iol Chem And Pharma Ltd

Community Sentiment

What are other investors saying about Iol Chem And Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.